Top

BMC Cancer

Published in:

01-12-2020 | Lung Cancer | Research article

The association of depressive symptoms, personality traits, and sociodemographic factors with health-related quality of life and quality of life in patients with advanced-stage lung cancer: an observational multi-center cohort study

Authors: Mark de Mol, Sabine Visser, Joachim Aerts, Paul Lodder, Nico van Walree, Huub Belderbos, Brenda den Oudsten

Published in: BMC Cancer | Issue 1/2020

Abstract

Background

Identification of patient-related factors associated with Health-Related Quality of Life (HRQoL) and Quality of Life (QoL) at the start of treatment may identify patients who are prone to a decrease in HRQoL and/or QoL resulting from chemotherapy. Identification of these factors may offer opportunities to enhance patient care during treatment by adapting communication strategies and directing medical and psychological interventions. The aim was to examine the association of sociodemographic factors, personality traits, and depressive symptoms with HRQoL and QoL in patients with advanced-stage lung cancer at the start of chemotherapy.

Methods

Patients (n = 151) completed the State-Trait Anxiety Inventory (trait anxiety subscale), the Neuroticism-Extraversion-Openness-Five Factor Inventory (NEO-FFI), the Center for Epidemiologic Studies Depression (CES-D), the World Health Organization Quality of Life-BREF (WHOQOL-BREF), and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). Simple linear regression analyses were performed to select HRQoL and QoL associated factors (a P ≤ 0.10 was used to prevent non-identification of important factors) followed by multiple linear regression analyses (P ≤ 0.05).

Results

In the multiple regression analyses, CES-D score (β = − 0.63 to − 0.53; P-values < 0.001) was most often associated with the WHOQOL-BREF domains and general facet, whereas CES-D score (β = − 0.67 to − 0.40; P-values < 0.001) and Eastern Cooperative Oncology Group (ECOG) performance status (β = − 0.30 to − 0.30; P-values < 0.001) were most often associated with the scales of the EORTC QLQ-C30. Personality traits were not related with HRQoL or QoL except for trait anxiety (Role functioning: β = 0.30; P = 0.02, Environment: β = − 0.39; P = 0.007) and conscientiousness (Physical health: β = 0.20; P-value < 0.04).

Conclusions

Higher scores on depressive symptoms and ECOG performance status were related to lower HRQoL and QoL in patients with advanced-stage non-small cell lung cancer. Supportive care interventions aimed at improvement of depressive symptoms and performance score may facilitate an increase of HRQoL and/or QoL during treatment.

Available only for authorised users

Chansky K, Detterbeck FC, Nicholson AG, Rusch VW, Vallieres E, Groome P, Kennedy C, Krasnik M, Peake M, Shemanski L, Bolejack V, Crowley JJ, Asamura H, Rami-Porta R, Staging I, Prognostic Factors Committee AB, Participating I. The IASLC lung Cancer Staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung Cancer. J Thoracic Oncol. 2017;12(7):1109–21. https://doi.org/10.1016/j.jtho.2017.04.011.CrossRef

Al-Batran SE, Hozaeel W, Tauchert FK, Hofheinz RD, Hinke A, Windemuth-Kieselbach C, Hubner A, Burmester M, Koenigsmann M, Wiegand J, Zur Hausen G, Linsse B, Kuhl R, Pauligk C, Arbeitsgemeinschaft Internistische O. The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax). Ann Oncol. 2015;26(6):1244–8. https://doi.org/10.1093/annonc/mdv129.CrossRefPubMed

De Vries JDOBL. The choice determines the success. Nederlands tijdschrift voor Orthopaedie. 2014;21(2):39–42.

Chaar EA, Hallit S, Hajj A, Aaraj R, Kattan J, Jabbour H, Khabbaz LR. Evaluating the impact of spirituality on the quality of life, anxiety, and depression among patients with cancer: an observational transversal study. Support Care Cancer. 2018;26(8):2581–90. https://doi.org/10.1007/s00520-018-4089-1.CrossRefPubMed

Jordhoy MS, Fayers P, Loge JH, Saltnes T, Ahlner-Elmqvist M, Kaasa S. Quality of life in advanced cancer patients: the impact of sociodemographic and medical characteristics. Br J Cancer. 2001;85(10):1478–85. https://doi.org/10.1054/bjoc.2001.2116.CrossRefPubMedPubMedCentral

Lundh Hagelin C, Seiger A, Furst CJ. Quality of life in terminal care--with special reference to age, gender and marital status. Support Care Cancer. 2006;14(4):320–8. https://doi.org/10.1007/s00520-005-0886-4.CrossRefPubMed

Zimmermann C, Burman D, Swami N, Krzyzanowska MK, Leighl N, Moore M, Rodin G, Tannock I. Determinants of quality of life in patients with advanced cancer. Support Care Cancer. 2011;19(5):621–9. https://doi.org/10.1007/s00520-010-0866-1.CrossRefPubMed

Skarstein J, Aass N, Fossa SD, Skovlund E, Dahl AA. Anxiety and depression in cancer patients: relation between the hospital anxiety and depression scale and the European Organization for Research and Treatment of Cancer Core quality of life questionnaire. J Psychosom Res. 2000;49(1):27–34.CrossRefPubMed

Mystakidou K, Tsilika E, Parpa E, Katsouda E, Galanos A, Vlahos L. Assessment of anxiety and depression in advanced cancer patients and their relationship with quality of life. Qual Life Res. 2005;14(8):1825–33. https://doi.org/10.1007/s11136-005-4324-3.CrossRefPubMed

10.

Brouwers C, Kupper N, Pelle AJ, Szabo BM, Westerhuis BL, Denollet J. Depressive symptoms in outpatients with heart failure: importance of inflammatory biomarkers, disease severity and personality. Psychol Health. 2014;29(5):564–82. https://doi.org/10.1080/08870446.2013.869813.CrossRefPubMed

11.

de Voogd JN, Wempe JB, Postema K, van Sonderen E, Ranchor AV, Coyne JC, Sanderman R. More evidence that depressive symptoms predict mortality in COPD patients: is type D personality an alternative explanation? Ann Behav Med. 2009;38(2):86–93. https://doi.org/10.1007/s12160-009-9105-8.CrossRefPubMed

12.

Pedersen SS, Herrmann-Lingen C, de Jonge P, Scherer M. Type D personality is a predictor of poor emotional quality of life in primary care heart failure patients independent of depressive symptoms and New York heart association functional class. J Behav Med. 2010;33(1):72–80. https://doi.org/10.1007/s10865-009-9236-1.CrossRefPubMed

13.

van der Steeg AF, De Vries J, Roukema JA. Anxious personality and breast cancer: possible negative impact on quality of life after breast-conserving therapy. World J Surg. 2010;34(7):1453–60. https://doi.org/10.1007/s00268-010-0526-0.CrossRefPubMedPubMedCentral

14.

Hollen PJ, Gralla RJ, Kris MG, Eberly SW, Cox C. Normative data and trends in quality of life from the lung Cancer symptom scale (LCSS). Support Care Cancer. 1999;7(3):140–8.CrossRefPubMed

15.

Temel JS, Greer JA, El-Jawahri A, Pirl WF, Park ER, Jackson VA, Back AL, Kamdar M, Jacobsen J, Chittenden EH, Rinaldi SP, Gallagher ER, Eusebio JR, Li Z, Muzikansky A, Ryan DP. Effects of early integrated palliative Care in Patients with Lung and GI Cancer: a randomized clinical trial. J Clin Oncol. 2017;35(8):834–41. https://doi.org/10.1200/JCO.2016.70.5046.CrossRefPubMed

16.

Skevington SM, Lotfy M, O'Connell KA, Group W. The World Health Organization's WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res. 2004;13(2):299–310.CrossRefPubMed

17.

The WHOQOL Group. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med. 1998;28(3):551–8.

18.

Lin CY, Yang SC, Lai WW, Su WC, Wang JD. Rasch models suggested the satisfactory psychometric properties of the World Health Organization quality of life-brief among lung cancer patients. J Health Psychol. 2015. https://doi.org/10.1177/1359105315603474.

19.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.CrossRefPubMed

20.

Luckett T, King MT, Butow PN, Oguchi M, Rankin N, Price MA, Hackl NA, Heading G. Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations. Ann Oncol. 2011;22(10):2179–90. https://doi.org/10.1093/annonc/mdq721.CrossRefPubMed

21.

Spielberger CD, Gorsuch RL, Lushene RE. STAI manual for the state-trait anxiety inventory. Palo Alto CA: Consulting Psychologists Press; 1970.

22.

De Vries J, Van Heck GL. Development of a short version of the Dutch version of the Spielberger STAI trait anxiety scale in women suspected of breast cancer and breast cancer survivors. J Clin Psychol Med Settings. 2013;20(2):215–26. https://doi.org/10.1007/s10880-012-9325-0.CrossRefPubMed

23.

Van Der Ploeg HM, Defares PB, Spielberger CD. Handleiding bij de Zelf-Beoordelings Vragenlijst, ZBV: Een Nederlandstalige Bewerking van de Spielberger State-Trait Anxiety Inventory, STAI-DY. Lisse: Swets & Zeitlinger; 1980.

24.

Costa PT, McCrae, R.R. (1989) The NEO-PI/ FFI manual supplement. Odessa, Florida: Psychological Assessment Resources Inc.

25.

Costa PT, McCrae, R.R. (1992) Revised NEO personality inventory (NEO-PI-R) and the five factor inventory (NEO-FFI): professional manual. Odessa, Florida: Psychological Assessment Resources Inc.

26.

Hoekstra HA, Ormel J, De Fruyt F. NEO-PI-R/NEO-FFI Big Five Persoonlijkheidsvragenlijst: Handleiding. Lisse, Nederland: Harcourt Assessment; 2003.

27.

Schwartz ES, Chapman BP, Duberstein PR, Weinstock-Guttman B, Benedict RH. The NEO-FFI in multiple sclerosis: internal consistency, factorial validity, and correspondence between self and informant reports. Assessment. 2011;18(1):39–49. https://doi.org/10.1177/1073191110368482.CrossRefPubMed

28.

Lima MP, Machado WL, Irigaray TQ. Predictive factors of treatment adherence in cancer outpatients. Psycho-oncology. 2018;27(12):2823–8. https://doi.org/10.1002/pon.4897.CrossRefPubMed

29.

Morgan S, Cooper B, Paul S, Hammer MJ, Conley YP, Levine JD, Miaskowski C, Dunn LB. Association of Personality Profiles with depressive, anxiety, and Cancer-related symptoms in patients undergoing chemotherapy. Personal Individ Differ. 2017;117:130–8. https://doi.org/10.1016/j.paid.2017.05.039.CrossRef

30.

Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measures. 1977;1:385–401.CrossRef

31.

Schroevers MJ, Sanderman R, van Sonderen E, Ranchor AV. The evaluation of the Center for Epidemiologic Studies Depression (CES-D) scale: depressed and positive affect in cancer patients and healthy reference subjects. Qual Life Res. 2000;9(9):1015–29.CrossRefPubMed

32.

Hanewald GJFP (1987) CES-D. De Nederlandse versie. Een onderzoek naar de betrouwbaarheid en de validiteit. Amsterdam, Vakgroep klinische Psychologie, Universiteit van Amsterdam, interne publikatie.

33.

Vodermaier A, Linden W, Siu C. Screening for emotional distress in cancer patients: a systematic review of assessment instruments. J Natl Cancer Inst. 2009;101(21):1464–88. https://doi.org/10.1093/jnci/djp336.CrossRefPubMedPubMedCentral

34.

Hann D, Winter K, Jacobsen P. Measurement of depressive symptoms in cancer patients: evaluation of the Center for Epidemiological Studies Depression Scale (CES-D). J Psychosom Res. 1999;46(5):437–43. https://doi.org/10.1016/s0022-3999(99)00004-5.CrossRefPubMed

35.

Green SB. How many subjects does it take to do a regression analysis? Multivar Behav Res. 1991;26(3):499–510.CrossRef

36.

Hosmer DW, Lemeshow S. Applied survival analysis: regression modeling of time to event data. New York: Wiley; 1999.

37.

Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley; 2000.CrossRef

38.

Hamann HA, Lee JW, Schiller JH, Horn L, Wagner LI, Chang VT, Fisch MJ. Clinician perceptions of care difficulty, quality of life, and symptom reports for lung cancer patients: an analysis from the symptom outcomes and practice patterns (SOAPP) study. J Thoracic Oncol. 2013;8(12):1474–83. https://doi.org/10.1097/01.JTO.0000437501.83763.5d.CrossRef

39.

van Montfort E, de Vries J, Arts R, Aerts JG, Kloover JS, Traa MJ. The relation between psychological profiles and quality of life in patients with lung cancer. Support Care Cancer. 2020;28(3):1359–67. https://doi.org/10.1007/s00520-019-04923-w.CrossRefPubMed

40.

Ramachandra P, Booth S, Pieters T, Vrotsou K, Huppert FA. A brief self-administered psychological intervention to improve well-being in patients with cancer: results from a feasibility study. Psycho-oncology. 2009;18(12):1323–6. https://doi.org/10.1002/pon.1516.CrossRefPubMed

41.

Pouy S, Attari Peikani F, Nourmohammadi H, Sanei P, Tarjoman A, Borji M (2018) Investigating the effect of mindfulness-based training on psychological status and quality of life in patients with breast Cancer. Asian Pacific journal of cancer prevention : APJCP 19 (7):1993-1998. Doi:10.22034/APJCP.2018.19.7.1993.

42.

Peddle-McIntyre CJ, Singh F, Thomas R, Newton RU, Galvao DA, Cavalheri V. Exercise training for advanced lung cancer. Cochrane Database Syst Rev. 2019;2:CD012685. https://doi.org/10.1002/14651858.CD012685.pub2.CrossRefPubMed

43.

Turcott JG, Del Rocio Guillen Nunez M, Flores-Estrada D, Onate-Ocana LF, Zatarain-Barron ZL, Barron F, Arrieta O. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer. 2018;26(9):3029–38. https://doi.org/10.1007/s00520-018-4154-9.CrossRefPubMed

44.

Ha EH, Cho YK. The mediating effects of self-esteem and optimism on the relationship between quality of life and depressive symptoms of breast Cancer patients. Psychiatry Investig. 2014;11(4):437–45. https://doi.org/10.4306/pi.2014.11.4.437.CrossRefPubMedPubMedCentral

45.

Hyphantis T, Almyroudi A, Paika V, Degner LF, Carvalho AF, Pavlidis N. Anxiety, depression and defense mechanisms associated with treatment decisional preferences and quality of life in non-metastatic breast cancer: a 1-year prospective study. Psycho-oncology. 2013;22(11):2470–7. https://doi.org/10.1002/pon.3308.CrossRefPubMed

46.

Gu W, Xu YM, Zhu JH, Zhong BL (2017) Depression and its impact on health-related quality of life among Chinese inpatients with lung cancer. Oncotarget 8 (62):104806-104812. Doi:https://doi.org/10.18632/oncotarget.21001.

47.

Alacacioglu A, Binicier O, Gungor O, Oztop I, Dirioz M, Yilmaz U. Quality of life, anxiety, and depression in Turkish colorectal cancer patients. Support Care Cancer. 2010;18(4):417–21. https://doi.org/10.1007/s00520-009-0679-2.CrossRefPubMed

48.

Karakoyun-Celik O, Gorken I, Sahin S, Orcin E, Alanyali H, Kinay M. Depression and anxiety levels in woman under follow-up for breast cancer: relationship to coping with cancer and quality of life. Med Oncol. 2010;27(1):108–13. https://doi.org/10.1007/s12032-009-9181-4.CrossRefPubMed

49.

Shimizu K, Nakaya N, Saito-Nakaya K, Akechi T, Yamada Y, Fujimori M, Ogawa A, Fujisawa D, Goto K, Iwasaki M, Tsugane S, Uchitomi Y. Clinical biopsychosocial risk factors for depression in lung cancer patients: a comprehensive analysis using data from the lung Cancer database project. Ann Oncol. 2012;23(8):1973–9. https://doi.org/10.1093/annonc/mds061.CrossRefPubMed

50.

Mols F, Thong MSY, de Poll-Franse LVV, Roukema JA, Denollet J. Type D (distressed) personality is associated with poor quality of life and mental health among 3080 cancer survivors. J Affect Disord. 2012;136(1–2):26–34. https://doi.org/10.1016/j.jad.2011.08.034.CrossRefPubMed

51.

Kim SR, Nho JH, Nam JH. Relationships among type-D personality, symptoms and quality of life in patients with ovarian cancer receiving chemotherapy. J Psychosom Obstet Gynaecol. 2018;39(4):289–96. https://doi.org/10.1080/0167482X.2017.1372416.CrossRefPubMed

52.

de Fruyt F, Denollet J. Type D personality: a five-factor model perspective. Psychol Health. 2002;17(5):671–83. https://doi.org/10.1080/08870440290025858.CrossRef

53.

Sajadinejad MS, Molavi H, Asgari K, Kalantari M, Adibi P. Personality dimensions and type D personality in female patients with ulcerative colitis. J Res Med Sci. 2012;17(10):898–904.PubMedPubMedCentral

54.

Kepka S, Baumann C, Anota A, Buron G, Spitz E, Auquier P, Guillemin F, Mercier M. The relationship between traits optimism and anxiety and health-related quality of life in patients hospitalized for chronic diseases: data from the SATISQOL study. Health Qual Life Outcomes. 2013;11:134. https://doi.org/10.1186/1477-7525-11-134.CrossRefPubMedPubMedCentral

55.

Mols F, Schoormans D, de Hingh I, Oerlemans S, Husson O. Symptoms of anxiety and depression among colorectal cancer survivors from the population-based, longitudinal PROFILES registry: prevalence, predictors, and impact on quality of life. Cancer. 2018;124(12):2621–8. https://doi.org/10.1002/cncr.31369.CrossRefPubMed

56.

da Rocha NS, Power MJ, Bushnell DM, Fleck MP. Is there a measurement overlap between depressive symptoms and quality of life? Compr Psychiatry. 2009;50(6):549–55. https://doi.org/10.1016/j.comppsych.2008.11.015.CrossRefPubMed

Title: The association of depressive symptoms, personality traits, and sociodemographic factors with health-related quality of life and quality of life in patients with advanced-stage lung cancer: an observational multi-center cohort study
Authors: Mark de Mol
Sabine Visser
Joachim Aerts
Paul Lodder
Nico van Walree
Huub Belderbos
Brenda den Oudsten
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Lung Cancer
Mood Disorders
Lung Cancer
Affective Disorder
Lung Cancer
Anxiety
Published in: BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-020-06823-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Simple calculation using anatomical features on pre-treatment verification CT for bladder volume estimation during radiation therapy for rectal cancer

Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival

CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma

NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial)

Exercise as a diagnostic and therapeutic tool for preventing cardiovascular morbidity in breast cancer patients– the BReast cancer EXercise InTervention (BREXIT) trial protocol

Expression of p53 N-terminal isoforms in B-cell precursor acute lymphoblastic leukemia and its correlation with clinicopathological profiles

Keynote webinar | Spotlight on antibody–drug conjugates in cancer